Amit Mehta, MD Douglas P. Beall, MD RADIOLOGY
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
CD133 Expression in Placenta Chorioangioma Presenting As a Giant Asymptomatic Mass
medicina Case Report CD133 Expression in Placenta Chorioangioma Presenting as a Giant Asymptomatic Mass Gianluca Di Massa 1,†, Guglielmo Stabile 2,† , Federico Romano 2 , Andrea Balduit 3 , Alessandro Mangogna 2,* , Beatrice Belmonte 4 , Pina Canu 1, Emma Bertucci 5, Giuseppe Ricci 2,6,‡ and Tiziana Salviato 1,‡ 1 Department of Diagnostic, Clinic and Public Health Medicine, University of Modena and Reggio Emilia, 41125 Modena, Italy; [email protected] (G.D.M.); [email protected] (P.C.); [email protected] (T.S.) 2 Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria, 65/1, 34137 Trieste, Italy; [email protected] (G.S.); [email protected] (F.R.); [email protected] (G.R.) 3 Department of Life Sciences, University of Trieste, 34127 Trieste, Italy; [email protected] 4 Tumor Immunology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90134 Palermo, Italy; [email protected] 5 Prenatal Medicine Unit, Obstetrics and Gynecology Unit, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, 41125 Modena, Italy; [email protected] 6 Department of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy * Correspondence: [email protected]; Tel.: +39-320-612-3370 † These authors contributed equally to this article. Citation: Di Massa, G.; Stabile, G.; ‡ These authors contributed equally to this article. Romano, F.; Balduit, A.; Mangogna, A.; Belmonte, B.; Canu, P.; Abstract: Background: Placental chorioangioma is the most common benign non-trophoblastic neo- Bertucci, E.; Ricci, G.; Salviato, T. -
Placenta 111 (2021) 33–46
Placenta 111 (2021) 33–46 Contents lists available at ScienceDirect Placenta journal homepage: www.elsevier.com/locate/placenta Review Placental pathology in cancer during pregnancy and after cancer treatment exposure Vera E.R.A. Wolters a, Christine A.R. Lok a, Sanne J. Gordijn b, Erica A. Wilthagen c, Neil J. Sebire d, T. Yee Khong e, J. Patrick van der Voorn f, Fred´ ´eric Amant a,g,* a Department of Gynecologic Oncology and Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute - Antoni van Leeuwenhoek and University Medical Centers Amsterdam, Plesmanlaan 121, 1066, CX Amsterdam, the Netherlands b Department of Gynaecology and Obstetrics, University of Groningen, University Medical Center Groningen, CB 20 Hanzeplein 1, 9713, GZ Groningen, the Netherlands c Scientific Information Service, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX Amsterdam, the Netherlands d Department of Paediatric Pathology, NIHR Great Ormond Street Hospital BRC, London, WC1N 3JH, United Kingdom e SA Pathology, Women’s and Children’s Hospital, 72 King William Road, North Adelaide, SA5006, Australia f Department of Pathology, University Medical Centers Amsterdam, Location VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands g Department of Oncology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium ARTICLE INFO ABSTRACT Keywords: Cancer during pregnancy has been associated with (pathologically) small for gestational age offspring, especially Placenta after exposure to chemotherapy in utero. These infants are most likely growth restricted, but sonographic results Cancer are often lacking. In view of the paucity of data on underlying pathophysiological mechanisms, the objective was Pregnancy to summarize all studies investigating placental pathology related to cancer(treatment). -
Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer
JOP. J Pancreas (Online) 2017 Sep 29; 18(5):365-368. REVIEW ARTICLE The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer Ahmad Malli, Feng Li, Darwin L Conwell, Zobeida Cruz-Monserrate, Hisham Hussan, Somashekar G Krishna Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA ABSTRACT Obesity is a global epidemic as recognized by the World Health Organization. Obesity and its related comorbid conditions were recognized to have an important role in a multitude of acute, chronic, and critical illnesses including acute pancreatitis, nonalcoholic fatty pancreas disease, and pancreatic cancer. This review summarizes the impact of adiposity on a spectrum of pancreatic diseases. INTRODUCTION and even higher mortality in the setting of AP based on multiple reports [8, 9, 10, 11, 12]. Despite the rising incidence Obesity is a global epidemic as recognized by the World of AP over the past two decades, there has been a decrease Health Organization [1]. One third of the world’s population in its overall mortality rate without any obvious decrement is either overweight or obese, and it has doubled over the in the mortality rate among patients with concomitant AP past two decades with an alarming 70% increase in the and morbid obesity [12, 13]. Several prediction models and prevalence of morbid obesity from year 2000 to 2010 [2, risk scores were proposed to anticipate the severity and 3, 4]. Obesity and its related comorbid conditions were prognosis of patient with AP; however, their clinical utility recognized to have an important role in a multitude of is variable, not completely understood, and didn’t take acute, chronic, and critical pancreatic illnesses including obesity as a major contributor into consideration despite the acute pancreatitis, non-alcoholic fatty pancreas disease, aforementioned association [14]. -
Chapter 1 Cellular Reaction to Injury 3
Schneider_CH01-001-016.qxd 5/1/08 10:52 AM Page 1 chapter Cellular Reaction 1 to Injury I. ADAPTATION TO ENVIRONMENTAL STRESS A. Hypertrophy 1. Hypertrophy is an increase in the size of an organ or tissue due to an increase in the size of cells. 2. Other characteristics include an increase in protein synthesis and an increase in the size or number of intracellular organelles. 3. A cellular adaptation to increased workload results in hypertrophy, as exemplified by the increase in skeletal muscle mass associated with exercise and the enlargement of the left ventricle in hypertensive heart disease. B. Hyperplasia 1. Hyperplasia is an increase in the size of an organ or tissue caused by an increase in the number of cells. 2. It is exemplified by glandular proliferation in the breast during pregnancy. 3. In some cases, hyperplasia occurs together with hypertrophy. During pregnancy, uterine enlargement is caused by both hypertrophy and hyperplasia of the smooth muscle cells in the uterus. C. Aplasia 1. Aplasia is a failure of cell production. 2. During fetal development, aplasia results in agenesis, or absence of an organ due to failure of production. 3. Later in life, it can be caused by permanent loss of precursor cells in proliferative tissues, such as the bone marrow. D. Hypoplasia 1. Hypoplasia is a decrease in cell production that is less extreme than in aplasia. 2. It is seen in the partial lack of growth and maturation of gonadal structures in Turner syndrome and Klinefelter syndrome. E. Atrophy 1. Atrophy is a decrease in the size of an organ or tissue and results from a decrease in the mass of preexisting cells (Figure 1-1). -
Non-Cancerous Breast Conditions Fibrosis and Simple Cysts in The
cancer.org | 1.800.227.2345 Non-cancerous Breast Conditions ● Fibrosis and Simple Cysts ● Ductal or Lobular Hyperplasia ● Lobular Carcinoma in Situ (LCIS) ● Adenosis ● Fibroadenomas ● Phyllodes Tumors ● Intraductal Papillomas ● Granular Cell Tumors ● Fat Necrosis and Oil Cysts ● Mastitis ● Duct Ectasia ● Other Non-cancerous Breast Conditions Fibrosis and Simple Cysts in the Breast Many breast lumps turn out to be caused by fibrosis and/or cysts, which are non- cancerous (benign) changes in breast tissue that many women get at some time in their lives. These changes are sometimes called fibrocystic changes, and used to be called fibrocystic disease. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Fibrosis and cysts are most common in women of child-bearing age, but they can affect women of any age. They may be found in different parts of the breast and in both breasts at the same time. Fibrosis Fibrosis refers to a large amount of fibrous tissue, the same tissue that ligaments and scar tissue are made of. Areas of fibrosis feel rubbery, firm, or hard to the touch. Cysts Cysts are fluid-filled, round or oval sacs within the breasts. They are often felt as a round, movable lump, which might also be tender to the touch. They are most often found in women in their 40s, but they can occur in women of any age. Monthly hormone changes often cause cysts to get bigger and become painful and sometimes more noticeable just before the menstrual period. Cysts begin when fluid starts to build up inside the breast glands. Microcysts (tiny, microscopic cysts) are too small to feel and are found only when tissue is looked at under a microscope. -
Official Proceedings
Scientific Session Awards Abstracts presented at the Society’s annual meeting will be considered for the following awards: • The George Peters Award recognizes the best presentation by a breast fellow. In addition to a plaque, the winner receives $1,000. The winner is selected by the Society’s Publications Committee. The award was established in 2004 by the Society to honor Dr. George N. Peters, who was instrumental in bringing together the Susan G. Komen Breast Cancer Foundation, The American Society of Breast Surgeons, the American Society of Breast Disease, and the Society of Surgical Oncology to develop educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships. • The Scientific Presentation Award recognizes an outstanding presentation by a resident, fellow, or trainee. The winner of this award is also determined by the Publications Committee. In addition to a plaque, the winner receives $500. • All presenters are eligible for the Scientific Impact Award. The recipient of the award, selected by audience vote, is honored with a plaque. All awards are supported by The American Society of Breast Surgeons Foundation. The American Society of Breast Surgeons 2 2017 Official Proceedings Publications Committee Chair Judy C. Boughey, MD Members Charles Balch, MD Sarah Blair, MD Katherina Zabicki Calvillo, MD Suzanne Brooks Coopey, MD Emilia Diego, MD Jill Dietz, MD Mahmoud El-Tamer, MD Mehra Golshan, MD E. Shelley Hwang, MD Susan Kesmodel, MD Brigid Killelea, MD Michael Koretz, MD Henry Kuerer, MD, PhD Swati A. -
California Tumor Tissue Registry
" CALIFORNIA TUMOR TISSUE REGISTRY California Tumor Tissue Registry c/o: Departme.nt of Pathology and Human Anatomy Lorna Linda University Sebool of Medicine 11021 Campus Avenue, AH 335 Lorna Linda, California 92350 (909) 824-4788 FAX: (909) 478-4188 CON"ntiDUTOR: WllllanoTalbert, M.D. CASE NO. 1 ·NOVEMBER 1995 Long Beach, CA TISSUE FROM: Sple<on ACCESSION #27748 CLINICAL ABSTRACT: This 77-year-old maJe. bad a 1-1!2 year history of a myelodysplastic syndrome, Ilea ted with blood transfusions for anemia. G.I. bleeding with tany stools and a hemoglobin of 5.21<d to admission about two weeks prior to his death. He became febrile. Blood and urine cullures were sterile. Renal failure developed. He became obtunded and died. He did not have a leukenlic peripheral blood picture. GROSS PATHO LOGV: Autopsy revealed a 1750 gram spleen with a splenic ''abscess•• which was partially ruptured and contained by surrounding tissue. CONTRIDUTOR: William Talbert, M.D. CASE NO. 2 • NOVE~ffiER 1995 Long Beach, CA TISSUE FROM: Lung ACCESSION 1127760 CLINl CAL ABSTRACT: This 23-year-old Asian female bad hemoptysis for two years. Chest film revealed a 1.0 em mass which grew to 4 em under observation. Iron deficiency anemia was diagnosed preoperatively, with a hemoglobin of 10.7 grams. Needle biopsy of the mass revealed tissue with the same diagnosis as that made on the resected specimen. A right upper lobe lobectomy was performed . GROSS PATROLOGV: The 120 gram lung was 12 x 7 x 3.5 em. A 3.5 em well-cireuonscribed nodule was near the bronchial margin. -
Fat Necrosis
Fat necrosis This leaflet tells you about fat necrosis. It explains what fat necrosis is, how it’s diagnosed and what will happen if it needs to be followed up or treated. Benign breast conditions information provided by Breast Cancer Care Breast Cancer Care doesn’t just support people when they’ve been diagnosed with breast cancer. We also highlight the importance of early detection and provide up-to-date, expert information on breast conditions and breast health. If you have a question about breast health or breast cancer you can call us free on 0808 800 6000 or visit breastcancercare.org.uk We hope you find this information useful. If you’d like to help ensure we’re there for other people when they need us visit breastcancercare.org.uk/donate Central Office Breast Cancer Care Chester House 1–3 Brixton Road London SW9 6DE Phone: 0345 092 0800 Email: [email protected] Call our Helpline on 0808 800 6000 What is fat necrosis? Fat necrosis is a benign (not cancer) condition and does not increase your risk of developing breast cancer. It can occur anywhere in the breast and can affect women of any age. Men can also get fat necrosis, but this is very rare. Breasts are made up of lobules (milk-producing glands) and ducts (tubes that carry milk to the nipple). These are surrounded by glandular, fibrous and fatty tissue. Sometimes a lump can form if an area of the fatty breast tissue is damaged. This is called fat necrosis (necrosis is a medical term used to describe damaged or dead tissue). -
CELL INJURY Lecture 3
CELL INJURY Lecture 3 َ{ عَّلَم ْ ِٕ النَسَانَمَا لْم يَْعَلْم } Objectives: ● Understand the causes of and pathologic changes occurring in fatty change (steatosis), accumulations of exogenous and endogenous pigments (carbon, silica, iron, melanin, bilirubin and lipofuscin). ● Understand the causes of and differences between dystrophic and metastatic calcifications. Color Index: Girl’s Slides Important Male’s Notes Female’s Notes 1 Extra information Substance accumulate inside the cell in large Intracellular amounts and cause problems in the cell and the Accumulation: organ it’s called intracellular accumulation. The substance may accumulate in either the cytoplasm or nucleus. And can be: An abnormal A substance that’s substance not present A pigment: it can be always present in normal in the cell normally. an endogenous or an cell but has accumulated exogenous. excess e.g. water, lipids, glycogen, protein, carbohydrates It can be: Endogenous (from Exogenous (from outside inside the body) e.g. a the body) e.g. a mineral or product of abnormal component of bacteria. synthesis or metabolism. ExamplesExamples of of substances substance thatthat accumulateaccumulate in in excess excess in in the the cell: cell: A) water: abnormal accumulation of water in the cells is called hydropic change (cellular swelling). It’s an early sign of cellular degeneration in response to injury (note: it’s due to the failure of energy-dependent ion pump on the plasma membrane ⟶ leading to loss of normal ion & fluid homeostasis). B) Lipids: all major classes of lipids can accumulate in cells: • Accumulation of triglycerides ⟶ steatosis (Fatty change) • Accumulation of cholesterol ⟶ seen in the Atherosclerosis. -
Gynecologic and Obstetric Pathology (1127-1316)
VOLUME 31 | SUPPLEMENT 2 | MARCH 2018 MODERN PATHOLOGY 2018 ABSTRACTS GYNECOLOGIC AND OBSTETRIC PATHOLOGY (1127-1316) 107TH ANNUAL MEETING GEARED TO LEARN Vancouver Convention Centre MARCH 17-23, 2018 Vancouver, BC, Canada PLATFORM & 2018 ABSTRACTS POSTER PRESENTATIONS EDUCATION COMMITTEE Jason L. Hornick, Chair Amy Chadburn Rhonda Yantiss, Chair, Abstract Review Board Ashley M. Cimino-Mathews and Assignment Committee James R. Cook Laura W. Lamps, Chair, CME Subcommittee Carol F. Farver Steven D. Billings, Chair, Interactive Microscopy Meera R. Hameed Shree G. Sharma, Chair, Informatics Subcommittee Michelle S. Hirsch Raja R. Seethala, Short Course Coordinator Anna Marie Mulligan Ilan Weinreb, Chair, Subcommittee for Rish Pai Unique Live Course Offerings Vinita Parkash David B. Kaminsky, Executive Vice President Anil Parwani (Ex-Officio) Deepa Patil Aleodor (Doru) Andea Lakshmi Priya Kunju Zubair Baloch John D. Reith Olca Basturk Raja R. Seethala Gregory R. Bean, Pathologist-in-Training Kwun Wah Wen, Pathologist-in-Training Daniel J. Brat ABSTRACT REVIEW BOARD Narasimhan Agaram Mamta Gupta David Meredith Souzan Sanati Christina Arnold Omar Habeeb Dylan Miller Sandro Santagata Dan Berney Marc Halushka Roberto Miranda Anjali Saqi Ritu Bhalla Krisztina Hanley Elizabeth Morgan Frank Schneider Parul Bhargava Douglas Hartman Juan-Miguel Mosquera Michael Seidman Justin Bishop Yael Heher Atis Muehlenbachs Shree Sharma Jennifer Black Walter Henricks Raouf Nakhleh Jeanne Shen Thomas Brenn John Higgins Ericka Olgaard Steven Shen Fadi Brimo Jason -
Department of Obstetrics, Gynecology, and Reproductive Sciences
University of Pittsburgh School of Medicine DEPARTMENT OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE SCIENCES ANNUAL REPORT – ACADEMIC YEAR 2019 Tatomir, Shannon DEPARTMENT OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE SCIENCES UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE ANNUAL REPORT Academic Year 2019 July 1, 2018 – June 30, 2019 300 Halket Street Pittsburgh, PA 15213 412.641.4212 1 TABLE OF CONTENTS YEAR IN REVIEW MISSION STATEMENT ..................................................................................................................... 3 CHAIR’S ADDRESS ........................................................................................................................... 4 RECRUITMENTS ............................................................................................................................... 6 DEPARTURES ................................................................................................................................... 7 DEPARTMENT PROFESSIONAL MEMBERS ………………………………………………………………………………...8 DIVISION SUMMARIES OF RESEARCH, TEACHING AND CLINICAL PROGRAMS DIVISION OF GYNECOLOGIC SPECIALTIES .................................................................................... 11 DIVISION OF GYNECOLOGIC ONCOLOGY ..................................................................................... 24 DIVISION OF MATERNAL FETAL MEDICINE .................................................................................. 34 DIVISION OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY ........................................... -
Difference Between Apoptosis and Necrosis
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/315763939 Difference Between Apoptosis and Necrosis Article · April 2017 CITATIONS READS 0 22,403 1 author: Lakna Panawala Difference Between, Sydney, Australia 246 PUBLICATIONS 16 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Biochemistry View project Evolution View project All content following this page was uploaded by Lakna Panawala on 04 April 2017. The user has requested enhancement of the downloaded file. 4/4/2017 Difference Between Apoptosis and Necrosis | Definition, Process, Function, Comparison EXPLORE Type here to search... EXPLORE Home » Science » Biology » Cell Biology » Difference Between Apoptosis and Necrosis Difference Between Apoptosis and Necrosis April 4, 2017 • by Lakna • 7 min read 0 Stunning images of cells Main Difference – Apoptosis vs AAT Bioquest Discover how scientists use immunofluorescence to Necrosis capture beautiful cell images! Go to aatbio.com/science/biology Apoptosis and necrosis are two mechanisms involved in the Start Download View PDF cell death in multicellular organisms. Apoptosis is considered Convert From Doc to PDF, PDF to Doc Simply With The Free Online App! Go to download.fromdoctopdf.com as a naturally occurring physiological process whereas Instant smartness necrosis is a pathological process, which is caused by external Smarten up and impress the world. Access 50+ agents like toxins, trauma, and infections. Apoptosis is a courses developed by experts. Go to pages.mobileacademy.com highly regulated, timely process whereas the necrosis is an Structural Biology unregulated, random process. Inflammation and tissue damage Get Closer to Your Samples With TEM Imaging Tools Go to gatan.com/LifeScience are observed in necrosis.